U2AF1L3 Inhibitors

Chemical inhibitors of U2AF1L3 function primarily by targeting components of the spliceosome, a critical complex responsible for the splicing of pre-mRNA. Pladienolide B, E7107, Sudemycin D6, Meayamycin, Isoginkgetin, Spliceostatin A, Madrasin, Tetrocarcin A, Herboxidiene, FR901464, and Thailanstatin A are compounds that directly interfere with the splicing machinery by binding to and inhibiting various components, especially the SF3b complex. The SF3b complex is essential for the recognition of branch point sequences in pre-mRNA and is crucial for the assembly and function of the spliceosome. By inhibiting SF3b, these compounds effectively disrupt the splicing process. The disruption of splicing prevents U2AF1L3 from fulfilling its role in the precise excision and ligation of introns and exons, which is a vital step in the generation of mature mRNA.

Moreover, compounds such as Placetin A, which inhibits RNA polymerase II, indirectly affect U2AF1L3 by halting the transcription of RNA. Without the synthesis of pre-mRNA, the substrate for splicing is absent, and thus U2AF1L3's function is not utilized. This demonstrates the interconnectedness of transcription and splicing, where the inhibition of one process can cascade to affect the other. Although U2AF1L3 is not directly inhibited by Placetin A, the end result is a functional inhibition of U2AF1L3 due to the lack of pre-mRNA splicing substrate.